apyx (190143220)
https://cordis.europa.eu/project/id/190143220
Horizon Europe (2021-2027)
The first non-surgical repair for Pelvic Organ Prolapse
EIC Accelerator Open 2023 (HORIZON-EIC-2023-ACCELERATOROPEN-01)
surgical procedures
2023-10-01 Start Date (YY-MM-DD)
2025-09-30 End Date (YY-MM-DD)
€ 5,067,216
Description
Pelvic Organ Prolapse (POP) affects nearly 50% of women over 40 years old globally. 89% of the cases seek treatment for symptomatic early stage prolapse. Despite the high prevalence and the progression of POP over time, patients currently cannot be offered a repair solution until the condition worsens enough for surgical intervention. However, the surgical interventions of prolapse have several side effects like prolonged recovery, pelvic pain and relapses of POP. Escala Medical has developed a minimally invasive and incision-free repair intervention for early-stage POP repair - Apyx. Apyx is the first medical device for treating early stage prolapse, regaining quality of life and prevention of prolapse deterioration for the vast majority, currently un-addressed, POP sufferers. The EIC project will finalize the development of Apyx, conduct clinical trials, and support scale-up and commercialization activities.
Complicit Organisations
1 Israeli organisation participates in apyx.Country | Organisation (ID) | VAT Number | Role | Activity Type | Total Cost | EC Contribution | Net EC Contribution |
---|---|---|---|---|---|---|---|
Israel | ESCALA MEDICAL LTD (891363459) | IL515158582 | coordinator | PRC | € 5,067,216 | € 2,500,000 | € 2,500,000 |